表紙
市場調査レポート

再調合戦略:新技術によるライフサイクル管理を超えた利用拡大

Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management

発行 CBR Pharma Insights 商品コード 290378
出版日 ページ情報 英文 51 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
再調合戦略:新技術によるライフサイクル管理を超えた利用拡大 Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management
出版日: 2012年01月15日 ページ情報: 英文 51 Pages
概要

再調合は世界の製薬業界において、投資収益を最大化しながら、治療オプションの拡大・患者経験の改善を同時に達成するための重要な役割を果たしています。今後も、再調合はライフサイクル管理戦略として多用され続け、特許失効前の売上高拡大に貢献していくものと思われます。ただし、その実現のためには、各企業は再調合の意義を事前に十分に示しておく必要があります。具体的傾向としては、生物製剤の活用や、服薬回数の軽減による利便性の改善などが挙げられます。

当レポートでは、世界の医薬品産業における再調合の現状とあり方について分析し、再調合戦略の概要や意義、主な促進要因、放出制御製剤における再調合の戦略・手法などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 再調合戦略の概要

  • 再調合とは何か?
  • なぜ大手製薬企業を再調合へと進んでいくのか?
  • 大手製薬企業にとっての再調合の重要性
  • 再調合戦略の成功に必要なもの
  • 再調合戦略の最適化
  • 薬剤再調合:主なオプション

第2章 医薬品市場での再調合の主な促進要因の分析

  • 促進要因としての薬剤送達企業と再調合専門企業
  • ライフサイクル管理の主要オプションとしての再調合
  • 生物学的療法と「バイオベター」の台頭
  • 新たな技術
    • 経口式崩壊錠
    • 改竄防止技術
    • ナノテクノロジー

第3章 放出制御(コントロールリリース)再調合戦略への注目

  • 経口式放出制御
    • オプション
    • 利用される技術
    • ケーススタディの分析
    • 技術プロバイダーのプロファイル
  • 注射式放出制御
    • 技術プロバイダーのプロファイル
    • ケーススタディの分析

付録

目次
Product Code: CBRSV029

Reformulation performs a key role in the pharmaceutical industry enabling companies to maximize their returns on investment while broadening treatment options and improving patient experience. It's potential to rejuvenate R&D pipelines in the future as new technologies emerge compliment its position as a key lifecycle management strategy.

Reformulation will continue to be a much used lifecycle management strategy, enabling companies to boost sales before patent expiry and in ideal cases protect sales after generics enter. However in order to achieve this companies must focus increasingly on demonstrating provable benefits, ideally in head to head trials against the original product. This has become necessary as increasingly cost conscious healthcare providers promote the use of generic therapies unless clear advantages are demonstrated.

Biologics increasing dominance of the pharmaceutical market opens new opportunities in reformulation and will drive the sectors future success. Opportunities to deliver less frequent dosing or more convenient and lower cost formulations will continue to drive the development of new technologies.

The report, "Reformulation Strategies - New Technologies Extend Use Beyond Lifecycle Management", has been written to support companies with their strategic plans to maximize product portfolios and thus increase revenues across the lifecycles of their products. The insights, analysis, and support provided can be used throughout the pharma, biotech, and generics industries.

Scope

  • Introduction to reformulation strategies
  • Analysis of the key drivers of reformulation in the pharmaceutical market including coverage of new technologies such as orally disintegrating tablets, anti-tamper technologies and nanotechnology
  • Analysis of controlled release reformulation strategies - oral controlled release and injectable controlled release

Key Reasons to Purchase

  • Learn what drug reformulation is and why it is such a valuable lifecycle management tool for both pharmaceutical and biotech companies
  • Assess the opportunities to use reformulation to extend & grow the revenues for your product along with which types of reformulation best fit your needs
  • Understand the new technologies that are now available to use to support your reformulation strategy
  • Benefit from the analysis of multiple case studies to help support your company's/brand's strategy moving forward
  • Understand how reformulation can be a successful tool to reinvigorate your company's R&D pipeline, opening up new opportunities for past projects which were unsuccessful

Table of Contents

Chapter 1: Introduction to reformulation strategies

  • What is reformulation
  • What drives pharma companies to reformulate
  • The importance of reformulation to big pharma
  • What makes a successful reformulation strategy
  • Optimizing reformulation strategies
  • Drug formulations: the main options

Chapter 2: Analysis of the key drivers of reformulation in the pharmaceutical market

  • Drug delivery companies and reformulation specialists as a driving force
  • Reformulation a key option in lifecycle management
  • The rise of biologic therapies and "biobetters"
  • New technologies:
    • orally disintegrating tablets
    • anti-tamper technologies
    • nanotechnology.

Chapter 3: Focus on controlled release reformulation strategies

  • Oral controlled release:
    • the options
    • technologies used
    • case study analysis
    • technology provider profiles
  • Injectable controlled release:
    • technology provider profiles
    • case study analysis

Appendix

Back to Top